A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

医学 超重 内科学 肥胖 老年学 物理疗法 随机对照试验
作者
Linong Ji,Hongwei� Jiang,Zhifeng Cheng,Wei Qiu,Lin Liao,Yawei Zhang,Xiaoli Li,Shuguang Pang,Lihui Zhang,Liming Chen,Tao Yang,Li Yan,Shen Qu,Jie Wen,Jieyu Gu,Huan Deng,Yanqi Wang,Li Li,Han Han‐Zhang,Qingyang Ma
出处
期刊:Nature Communications [Nature Portfolio]
卷期号:14 (1): 8289-8289 被引量:127
标识
DOI:10.1038/s41467-023-44067-4
摘要

Abstract Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy and safety of 24-week treatment of mazdutide up to 6 mg in Chinese overweight adults or adults with obesity, as an interim analysis of a randomised, two-part (low doses up to 6 mg and high dose of 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913). Overweight adults (body-mass index [BMI] ≥24 kg/m 2 ) accompanied by hyperphagia and/or at least one obesity-related comorbidity or adults with obesity (BMI ≥ 28 kg/m 2 ) were randomly assigned (3:1:3:1:3:1) to once-weekly mazdutide 3 mg, 4.5 mg, 6 mg or matching placebo at 20 hospitals in China. The primary endpoint was the percentage change from baseline to week 24 in body weight. A total of 248 participants were randomised to mazdutide 3 mg ( n = 62), 4.5 mg ( n = 63), 6 mg ( n = 61) or placebo ( n = 62). The mean percentage changes from baseline to week 24 in body weight were −6.7% (SE 0.7) with mazdutide 3 mg, −10.4% (0.7) with 4.5 mg, −11.3% (0.7) with 6 mg and 1.0% (0.7) with placebo, with treatment difference versus placebo ranging from −7.7% to −12.3% (all p < 0.0001). All mazdutide doses were well tolerated and the most common adverse events included diarrhoea, nausea and upper respiratory tract infection. In summary, in Chinese overweight adults or adults with obesity, 24-week treatment with mazdutide up to 6 mg was safe and led to robust and clinically meaningful body weight reduction.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小马甲的应助被科研通管家采纳,获得10
刚刚
黎明完成签到 ,获得积分10
刚刚
呆萌安双发布了新的文献求助10
刚刚
刚刚
ding的应助被YXL采纳,获得10
刚刚
zimablue完成签到,获得积分10
刚刚
研友_VZG7GZ的应助被科研通管家采纳,获得10
1秒前
orixero的应助被科研通管家采纳,获得10
1秒前
思源的应助被科研通管家采纳,获得10
1秒前
1秒前
molihuakai的应助被科研通管家采纳,获得10
1秒前
小蘑菇的应助被科研通管家采纳,获得10
1秒前
sml的应助被科研通管家采纳,获得30
1秒前
搜集达人的应助被科研通管家采纳,获得10
1秒前
故意的驳发布了新的文献求助10
1秒前
丘比特的应助被科研通管家采纳,获得10
1秒前
科目三的应助被111采纳,获得10
2秒前
爆米花的应助被科研通管家采纳,获得10
2秒前
蓝天的应助被科研通管家采纳,获得10
2秒前
万能图书馆的应助被windli采纳,获得10
2秒前
领导范儿的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
2秒前
乐乐的应助被科研通管家采纳,获得10
2秒前
2秒前
领导范儿的应助被科研通管家采纳,获得10
2秒前
所所的应助被拉塞尔....采纳,获得10
2秒前
2秒前
qdd发布了新的文献求助10
3秒前
汉堡包的应助被好的呢采纳,获得10
3秒前
3秒前
3秒前
4秒前
隐形曼青的应助被鲤鱼蓝天采纳,获得10
4秒前
专注越彬完成签到,获得积分10
4秒前
4秒前
4秒前
FashionBoy的应助被初景采纳,获得10
4秒前
科研通AI6.2的应助被Bessie采纳,获得10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162816
求助须知:如何正确求助?哪些是违规求助? 9557103
关于积分的说明 21738393
捐赠科研通 7753330
什么是DOI,文献DOI怎么找? 3427963
关于科研通互助平台的介绍 2552742
邀请新用户注册赠送积分活动 2472556